Covaxin proven safe for children of 2-18 years age group in phase III study: Bharat Biotech

The clinical trial conducted in the pediatric population has shown safety, less reactogenic, and robust immunogenicity. The data was submitted to the Central Drugs Standard Control Organisation (CDSCO) in October 2021, and received a nod for emergency use in children aged 6-18 years, Bharat Biotech said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CEcgjfv
via IFTTT